|
1
|
Stearns V, Schneider B, Henry NL, Hayes DF
and Flockhart DA: Breast cancer treatment and ovarian failure: risk
factors and emerging genetic determinants. Nat Rev Cancer.
6:886–893. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chiang CT, Way TD and Lin JK: Sensitizing
HER2-overexpressing cancer cells to luteolin-induced apoptosis
through suppressing p21WAF1/CIP1 expression with
rapamycin. Mol Cancer Ther. 6:2127–2138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu D and Hung MC: Overexpression of ErbB2
in cancer and ErbB2-targeting strategies. Oncogene. 19:6115–6121.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meric-Bernstam F and Hung MC: Advances in
targeting human epidermal growth factor receptor-2 signaling for
cancer therapy. Clin Cancer Res. 12:6326–6330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Esteva FJ, Yu D, Hung MC and Hortobagyi
GN: Molecular predictors of response to trastuzumab and lapatinib
in breast cancer. Nat Rev Clin Oncol. 7:98–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vogel CL, Cobleigh MA, Tripathy D, et al:
Efficacy and safety of trastuzumab as a single agent in first-line
treatment of HER2-overexpressing metastatic breast cancer. J Clin
Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cardoso F, Piccart MJ, Durbecq V and Di
Leo A: Resistance to trastuzumab: a necessary evil or a temporary
challenge? Clin Breast Cancer. 3:247–257. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lan KH, Lu CH and Yu D: Mechanisms of
trastuzumab resistance and their clinical implications. Ann NY Acad
Sci. 1059:70–75. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Trepel J, Mollapour M, Giaccone G and
Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev
Cancer. 10:537–549. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu W, Mimnaugh E, Rosser MF, Nicchitta C,
Marcu M, Yarden Y and Neckers L: Sensitivity of mature Erbb2 to
geldanamycin is conferred by its kinase domain and is mediated by
the chaperone protein Hsp90. J Biol Chem. 276:3702–3708. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Richter K, Reinstein J and Buchner J: A
Grp on the Hsp90 mechanism. Mol Cell. 28:177–179. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Solit DB, Zheng FF, Drobnjak M, et al:
17-Allylamino-17-demethoxygeldanamycin induces the degradation of
androgen receptor and HER-2/neu and inhibits the growth of prostate
cancer xenografts. Clin Cancer Res. 8:986–993. 2002.PubMed/NCBI
|
|
14
|
Ko FN, Wu CC, Kuo SC, Lee FY and Teng CM:
YC-1, a novel activator of platelet guanylate cyclase. Blood.
84:4226–4233. 1994.PubMed/NCBI
|
|
15
|
Chou LC, Huang LJ, Yang JS, Lee FY, Teng
CM and Kuo SC: Synthesis of furopyrazol analogs of
1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) as novel
anti-leukemia agents. Bioorg Med Chem. 15:1732–1740. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan SL, Guh JH, Peng CY, et al: YC-1
[3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits
endothelial cell functions induced by angiogenic factors in vitro
and angiogenesis in vivo models. J Pharmacol Exp Ther. 314:35–42.
2005.
|
|
17
|
Huang YT, Pan SL, Guh JH, Chang YL, Lee
FY, Kuo SC and Teng CM: YC-1 suppresses constitutive nuclear
factor-κB activation and induces apoptosis in human prostate cancer
cells. Mol Cancer Ther. 4:1628–1635. 2005.PubMed/NCBI
|
|
18
|
Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM,
Kim MS and Park JW: Inhibitory effect of YC-1 on the hypoxic
induction of erythropoietin and vascular endothelial growth factor
in Hep3B cells. Biochem Pharmacol. 61:947–954. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mujoo K, Sharin VG, Bryan NS, et al: Role
of nitric oxide signaling components in differentiation of
embryonic stem cells into myocardial cells. Proc Natl Acad Sci USA.
105:18924–18929. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yun S, Lee SH, Kang YH, et al: YC-1
enhances natural killer cell differentiation from hematopoietic
stem cells. Int Immunopharmacol. 10:481–486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou LC, Huang LJ, Hsu MH, et al:
Synthesis of
1-benzyl-3-(5-hydroxymethyl-2-furyl)selenolo[3,2-c]pyrazole
derivatives as new anticancer agents. Eur J Med Chem. 45:1395–1402.
2010.PubMed/NCBI
|
|
22
|
Way TD, Lee JC, Kuo DH, et al: Inhibition
of epidermal growth factor receptor signaling by Saussurea
involucrata, a rare traditional Chinese medicinal herb, in
human hormone-resistant prostate cancer PC-3 cells. J Agric Food
Chem. 58:3356–3365. 2010.PubMed/NCBI
|
|
23
|
Lin VC, Chou CH, Lin YC, et al: Osthole
suppresses fatty acid synthase expression in HER2-overexpressing
breast cancer cells through modulating Akt/mTOR pathway. J Agric
Food Chem. 58:4786–4793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Panaretou B, Prodromou C, Roe SM, O’Brien
R, Ladbury JE, Piper PW and Pearl LH: ATP binding and hydrolysis
are essential to the function of the Hsp90 molecular chaperone in
vivo. EMBO J. 17:4829–4836. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oude Munnink TH, Korte MA, Nagengast WB,
et al: 89 Zr-trastuzumab PET visualises HER2 downregulation by the
HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J
Cancer. 46:678–684. 2010.PubMed/NCBI
|
|
26
|
Evgenov OV, Pacher P, Schmidt PM, Haskó G,
Schmidt HH and Stasch JP: NO-independent stimulators and activators
of soluble guanylate cyclase: discovery and therapeutic potential.
Nat Rev Drug Discov. 5:755–768. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu XM, Peyton KJ, Mendelev NN, Wang H,
Tulis DA and Durante W: YC-1 stimulates the expression of gaseous
monoxide-generating enzymes in vascular smooth muscle cells. Mol
Pharmacol. 75:208–217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang SW, Pan SL, Guh JH, et al: YC-1
[3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl indazole] exhibits a novel
antiproliferative effect and arrests the cell cycle in G0-G1 in
human hepatocellular carcinoma cells. J Pharmacol Exp Ther.
312:917–925. 2005.
|
|
29
|
Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC,
Kim MS and Park JW: YC-1: a potential anticancer drug targeting
hypoxia-inducible factor 1. J Natl Cancer Inst. 95:516–525. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yeh WL, Lu DY, Lin CJ, Liou HC and Fu WM:
Inhibition of hypoxia-induced increase of blood-brain barrier
permeability by YC-1 through the antagonism of HIF-1α accumulation
and VEGF expression. Mol Pharmacol. 72:440–449. 2007.PubMed/NCBI
|
|
31
|
Zhao Q, Du J, Gu H, Teng X, Zhang Q, Qin H
and Liu N: Effects of YC-1 on hypoxia-inducible factor 1-driven
transcription activity, cell proliferative vitality, and apoptosis
in hypoxic human pancreatic cancer cells. Pancreas. 34:242–247.
2007. View Article : Google Scholar
|
|
32
|
Kamal A, Thao L, Sensintaffar J, Zhang L,
Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of
Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature.
425:407–410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sawai A, Chandarlapaty S, Greulich H, et
al: Inhibition of Hsp90 down-regulates mutant epidermal growth
factor receptor (EGFR) expression and sensitizes EGFR mutant tumors
to paclitaxel. Cancer Res. 68:589–596. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Morrow PK, Zambrana F and Esteva FJ:
Recent advances in systemic therapy: advances in systemic therapy
for HER2-positive metastatic breast cancer. Breast Cancer Res.
11:2072009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Allred DC, Clark GM, Tandon AK, et al:
HER-2/neu in node-negative breast cancer: prognostic significance
of overexpression influenced by the presence of in situ
carcinoma. J Clin Oncol. 10:599–605. 1992.PubMed/NCBI
|
|
36
|
Harris JR, Lippman ME, Veronesi U and
Willett W: Breast cancer (1). N Engl J Med. 327:319–328. 1992.
View Article : Google Scholar
|
|
37
|
Harris JR, Lippman ME, Veronesi U and
Willett W: Breast cancer (2). N Engl J Med. 327:390–398. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Harris JR, Lippman ME, Veronesi U and
Willett W: Breast cancer (3). N Engl J Med. 327:473–480. 1992.
View Article : Google Scholar
|
|
39
|
Felip E, Del Campo JM, Rubio D, Vidal MT,
Colomer R and Bermejo B: Overexpression of c-erbB-2 in epithelial
ovarian cancer. Prognostic value and relationship with response to
chemotherapy. Cancer. 75:2147–2152. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ramalingam SS, Egorin MJ, Ramanathan RK,
et al: A phase I study of 17-allylamino-17-demethoxygeldanamycin
combined with Taxol in patients with advanced solid malignancies.
Clin Cancer Res. 14:3456–3461. 2008. View Article : Google Scholar : PubMed/NCBI
|
